<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077750</url>
  </required_header>
  <id_info>
    <org_study_id>VBP-245-MCV</org_study_id>
    <nct_id>NCT03077750</nct_id>
  </id_info>
  <brief_title>A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloce BioPharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veloce BioPharma LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the
      Efficacy, Tolerability, and Safety of Topical VBP-245 in Pediatric Subjects for the Treatment
      of Molluscum Contagiosum (VBP-245-MCV).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in number of MCV lesions</measure>
    <time_frame>60 days</time_frame>
    <description>Number of lesions from baseline to day 60 will be counted and the reduction in number will be recorded.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Molluscum Contagiosum</condition>
  <arm_group>
    <arm_group_label>VBP-245</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VBP-245 Topical Gel Applied to Affected Area BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Gel Applied to Affected Area BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBP-245 Topical Gel</intervention_name>
    <description>Topical application BID</description>
    <arm_group_label>VBP-245</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle Control With No Active Pharmaceutical Ingredients</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria:

          1. Males or females aged 2-18 years at screening;

          2. MC diagnosed by a general physician, dermatologist or pediatrician who refers it and
             treatable by a topical agent;

          3. Individuals with at least 1, but not exceeding 15 molluscum selected in designated
             treatment area:

          4. Individuals whose treatment area is located anywhere on the body except for the
             following prohibited areas which include: eye area (including eyelids), lips, mouth
             cavity, nasal cavity, inner ear, palms of the hands, soles of the feet or the
             anogenital area;

          5. Free from any systemic or dermatologic disorder that, in the opinion of the
             investigator, will interfere with the study results or increase the risk of adverse
             advents;

          6. Free from atopic dermatitis in the treatment area that, in the opinion of the
             investigator, will potentially get inflamed or irritated during the course of
             treatment;

          7. Parent or guardian able to give appropriate informed consent as determined by the
             approving institutional review board (IRB);

          8. Individuals who are generally in good health as determined by the investigator;

          9. Willingness and ability of parent or guardian to read, understand, and sign the
             IRB-approved informed consent form after the nature of the study has been fully
             explained and questions have been answered;

         10. Individuals who are willing to not start any new products OTC or prescription
             treatments and discontinue any treatment the investigator feels may interfere with the
             evaluation of the test products;

         11. Individuals who are willing to avoid using cosmetic products, creams, salves, or
             ointments to the treatment area(s);

         12. Individuals who are willing and able to thoroughly follow the product use
             instructions, attend all the scheduled visits and successfully complete the study;

         13. Individuals who are willing and able to not begin any office based treatments for the
             duration of the study;

         14. Female subjects of childbearing age with negative pregnancy test at the enrolment time
             in the study;

         15. Female subjects who are not breastfeeding at the enrolment time in the study;

         16. Female subjects that do not intend to become pregnant during their participation in
             the study;

         17. Female subjects with reproductive potential must agree to practice medically
             acceptable form of birth control during the study â€¢ Medically acceptable forms of
             birth control that may be used by the subject and/or his/her partner include: o
             Established use of hormonal methods of contraception (oral, injected, implanted, patch
             or vaginal ring) Barrier methods of contraception with spermicide: condom or occlusive
             cap (diaphragm or cervical/Vault caps) with a spermicidal foam/gel/film/cream or
             suppository; o Intrauterine divide (IUD) or intrauterine system (IUS); o Surgical
             sterilization (vasectomy, tubal occlusion, bilateral salpingectomy); Abstinence from
             heterosexual intercourse; when this is in line with the preferred and usual lifestyle
             of the subject. Periodic abstinence (calendar, ovulation, symptothermal, post
             ovulation methods) and withdrawal are NOT acceptable methods of contraception

        Exclusion Criteria:

        Subjects meeting the following exclusion criteria will be excluded from the study:

          1. Mentally incompetent or unable or not willing to give written informed consent via
             parent or guardian or meet study requirements

          2. Known history of hypersensitivity to topical povidone-iodine

          3. Significant atopic dermatitis surrounding the molluscum contagiosum lesions as judged
             by the investigator

          4. Individual lesions greater than 5mm in diameter

          5. Pregnant, breastfeeding or unwilling to undergo an acceptable form of contraception
             for the duration of the study;

          6. Molluscum lesions located on the eye area (including eyelids), lips, mouth cavity,
             nasal cavity, inner ear, palms of the hands, soles of the feet or the anogenital area;

          7. Have participated in an investigational trial within 30 days prior to enrollment;

          8. Have required or will require systemic intake of immunosuppressive or immunomodulatory
             medication (including oral or parenteral corticosteroids) within 30 days prior to
             enrollment or during the course of the study.

          9. Have any uncontrolled current infection;

         10. Female subject who is pregnant, lactating planning to become pregnant, or is
             breastfeeding;

         11. Have any chronic or acute medical condition that, in the opinion of the investigator,
             may interfere with the study results or place the subject at undue risk (such as an
             immunodeficiency or relevant genetic syndrome);

         12. Have any active malignancy or are undergoing treatment for any malignancy other than
             non-melanoma skin cancer; Subjects viewed by the Principal Investigator as not being
             able to complete the study -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayashri Krishnan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>JSS Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philadelphia Institute of Dermatology</name>
      <address>
        <city>Fort Washington</city>
        <state>Pennsylvania</state>
        <zip>19034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkside Pediatrics</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatrics</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>viral skin disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molluscum Contagiosum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

